TABLE 8.
Commercial cholesterol-based liposomes.
| Commercial name | Composition | Type of drug | Application |
|---|---|---|---|
| LADR (small-sized liposomal Adriamycin) (Chen et al., 2005) | Cholesterol + egg phosphatidylcholine | doxorubicin HCl | Anti-Cancer |
| AmBisome (Dynarowicz-Łątka et al., 2003) | HSPC + DSPG + cholesterol | Amphotericin B | Anti-fungal |
| Doxil®/Caelyx®a (Wibroe et al., 2016) | HSPC + cholesterol + DSPE-PEG2,000 | Doxorubicin | Anti-Cancer |
| Myocet™ (Collier et al., 2017) | EPC + cholesterol | Citrate conjugated doxorubicin | Anti-Cancer |
| Marqibo® (Silverman and Deitcher, 2013) | Sphingomyelin + cholesterol | vincristine sulfate | Anti-Cancer |
| Abelcet® (Husain et al., 2010) | DMPC + DMPG | Amphotericin B | Anti-fungal |
| DaunoXome® (Lowis et al., 2006) | DSPC + cholesterol | Daunorubicin | Anti-Cancer |
| Depocyt® (Phuphanich et al., 2007; Crommelin et al., 2020) | Cholesterol + triolein + DOPC + DPPG | Cytarabine | Anti-Cancer |
| Lipo-dox (Huang et al., 2018; Weng et al., 2019) | DSPC + cholesterol + PEG 2000-DSPE | Doxorubicin | Anti-Cancer |
| Visudyne (Barnes et al., 2010; Jain et al., 2016; Rizvi et al., 2019) | EPG + DMPC | Verteporfin | PDT |
| DepoDur (Peravali et al., 2014) | Cholesterol + Triolein + DOPC + DPPG | Morphine sulfate | Pain control and management |
DSPG, Distearoyl-sn-glycero-3-phosphoglycerol.